Pfizer helps pump $103M into startup to develop new cancer therapies
A New York startup has been spun-out of Pfizer to develop clinical-stage experimental therapies.
Nascent medicine company SpringWorks Therapeutics completed a $103 million series A round led by the New York-based pharma giant with the help of Bain Capital, OrbiMed and LifeArc (formerly known as MRC Technology).
Pfizer (NYSE: PFE) granted SpringWorks the rights to help develop four drugs or t herapies that treat various conditions, including post-traumatic stress disorder and cancer.
Another New…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Anthony Noto Source Type: news
More News: Biotechnology | Cancer | Cancer & Oncology | Cancer Therapy | Health Management | Pfizer | Pharmaceuticals | Post Traumatic Stress Disorder